Nomic Bio Secures $42 Million in Oversubscribed Series B Funding to Enhance Protein Profiling Capabilities

Nomic Bio, a leader in protein profiling, has successfully completed a $42 million Series B funding round that was oversubscribed. This significant capital infusion will propel the company’s efforts to enhance its cutting-edge protein profiling platform and expand its commercial operations, catering to the rising demand in the proteomics field. Led by a prominent U.S.-based…

Read More

Arzeda Secures $38 Million in Oversubscribed Funding to Propel Protein Design Innovations

Arzeda, the Protein Design Company™, has successfully closed a $38 million oversubscribed funding round aimed at advancing its groundbreaking protein design technologies. This funding round attracted significant investments from Sofinnova Partners, Fall Line Capital, Sucden Ventures, Silver Blue, and the venture arm of W.L. Gore & Associates, known for their Gore-Tex® innovations. Previous supporters such…

Read More

PictorLabs Secures $30 Million in Series B Funding to Revolutionize Histopathology with AI

PictorLabs, an innovative software firm at the forefront of AI-driven histopathology, has successfully raised $30 million in its Series B funding round. This round was led by Insight Partners, a global software investment powerhouse, with continued support from M Ventures, the venture capital branch of Merck KGaA, Darmstadt, Germany, which previously led PictorLabs’ Series A…

Read More

Cellino Secures $25 Million Grant from ARPA-H to Revolutionize Biomanufacturing for Personalized Regenerative Medicine

In a landmark development for the field of regenerative medicine, Cellino Biotech, Inc. has been awarded up to $25 million in funding from the Advanced Research Projects Agency for Health (ARPA-H), a division within the U.S. Department of Health and Human Services. This grant will significantly advance Cellino’s NEBULA, a cutting-edge biomanufacturing technology designed to…

Read More

Radiant Biotherapeutics Secures $35 Million in Series A Funding to Propel Multabody™ Platform

Radiant Biotherapeutics, a cutting-edge biotechnology firm specializing in advanced antibody therapies, has announced the successful closure of a $35 million Series A financing round. This significant investment, spearheaded by the Bill & Melinda Gates Foundation and Amplitude Ventures, aims to further develop Radiant’s innovative Multabody™ platform, which is poised to revolutionize therapeutic approaches across various…

Read More

Qualifyze Secures $54 Million in Series B Funding to Revolutionize Supplier Risk Management in Life Sciences

In a significant boost for the Life Sciences industry, Qualifyze has announced a landmark $54 million Series B funding round. This investment, led by global software investment firm Insight Partners, alongside existing backers HV Capital, HarbourVest Partners, H14, and Cherry Ventures, is set to propel Qualifyze into a new phase of growth and innovation. With…

Read More

LifeSpan Vision Ventures Invests in Remedium Bio to Advance Pioneering Gene Therapy Platform

LifeSpan Vision Ventures has made a significant investment in Remedium Bio, a biotechnology firm renowned for its groundbreaking gene therapy platform, Prometheus™. This latest funding is set to propel Remedium Bio’s innovative approach to gene therapy into new realms of clinical research and application. Remedium Bio is at the forefront of biotechnology with its Prometheus™…

Read More

NanoSyrinx Secures £10M to Propel Revolutionary Nano Syringe Delivery Platform

In a significant boost to the biotech sector, NanoSyrinx, a trailblazer in targeted intracellular delivery technologies, has successfully completed a £10 million financing round. This pivotal investment will accelerate the development of NanoSyrinx’s cutting-edge nano syringe platform, designed to enhance the precision of biologic therapeutic delivery. NanoSyrinx’s innovative approach leverages naturally occurring ‘nano syringes’—microscopic delivery…

Read More

Sonoma Biotherapeutics Secures $45 Million Milestone Payment from Regeneron in Transformative Collaboration

Sonoma Biotherapeutics, Inc., a leading clinical-stage biotechnology firm specializing in engineered regulatory T cell (Treg) therapies, has achieved a significant milestone with a $45 million payment from Regeneron Pharmaceuticals, Inc. This milestone underscores the fruitful partnership between the two companies in developing advanced treatments for autoimmune diseases. The payment marks a pivotal point in Sonoma…

Read More

eGenesis Secures $191 Million in Series D Funding to Propel Kidney Transplant Innovation

eGenesis, a trailblazer in biotechnology with a focus on developing human-compatible engineered organs, has announced the successful completion of a $191 million Series D financing round. This substantial investment will propel the advancement of eGenesis’s lead product candidate, EGEN-2784, through its first-in-human clinical trials for kidney transplants. Additionally, the funds will facilitate the expansion of…

Read More